SCHEMBL478272

SCHEMBL478272

COC(=O)C=Cc1cc(Cl)ccc1-n1cnnn1

nearest known ligand 0.54

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
F11 P03951 19/20 0.54
KLKB1 P03952 7/20 0.54
F10 P00742 2/20 0.48
PLG P00747 2/20 0.48
PLAT P00750 1/20 0.48
PROC P04070 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL478270 1.00 F11 (0.54) F11KLKB1F10PLGPLAT
SCHEMBL478666 0.87 F11 (0.50) F11KLKB1
SCHEMBL478664 0.87 F11 (0.50) F11KLKB1
SCHEMBL14874260 0.86 F11 (0.51) F11KLKB1
SCHEMBL16648369 0.86 F11 (0.54) F11KLKB1F10PLGPLAT
SCHEMBL478538 0.85 F11 (0.53) F11KLKB1
SCHEMBL30194022 0.85 F11 (0.53) F11KLKB1
SCHEMBL478536 0.85 F11 (0.53) F11KLKB1
SCHEMBL20109426 0.84 F11 (0.52) F11KLKB1
SCHEMBL30480722 0.84 F11 (0.52) F11KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10239863-B2 Factor XIa inhibitors MERCK SHARP & DOHME CORP. (US) 2019-03-26 US disclosed
US-20180179180-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2018-06-28 US disclosed
US-20160257668-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2016-09-08 US disclosed
EP-3054944-A1 FACTOR XIa INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
US-20160229839-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2016-08-11 US disclosed
EP-3049435-A1 FACTOR XIA INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-03 EP disclosed
EP-2102189-B1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-07-29 EP disclosed
WO-2015054087-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
WO-2015047973-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-02 WO disclosed
EP-2152664-B1 DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-09-03 EP disclosed
US-20110028446-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-02-03 US disclosed
US-20110021492-A1 PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-01-27 US disclosed
EP-2265601-A1 PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS Bristol-Myers Squibb Company (US) 2010-12-29 EP disclosed
US-7842708-B2 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-11-30 US disclosed
US-20100173899-A1 DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-07-08 US disclosed
US-20100022506-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-01-28 US disclosed
US-20100016316-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-01-21 US disclosed
US-7626039-B2 Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-01 US disclosed
WO-2009114677-A1 PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-17 WO disclosed
US-20080161373-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB CO. 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021492-A1 PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS F11, F12, TFPI2 F11 1/4885KLKB1 17/4885F10 14/4885
US-20080161373-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS TFPI, F11, F12 F11 2/4885KLKB1 53/4885F10 12/4885
US-20180179180-A1 Factor XIa Inhibitors F11, SERPINC1, TFPI F11 1/4885KLKB1 14/4885F10 11/4885
US-20100016316-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS F12, TFPI, F11 F11 3/4885KLKB1 93/4885F10 11/4885
US-20160257668-A1 Factor XIa Inhibitors F11, SERPINC1, TFPI F11 1/4885KLKB1 14/4885F10 11/4885
US-10239863-B2 Factor XIa inhibitors F11, SERPINC1, TFPI F11 1/4885KLKB1 14/4885F10 11/4885
US-20160229839-A1 Factor XIa Inhibitors F11, SERPINC1, TFPI F11 1/4885KLKB1 14/4885F10 11/4885
US-20100173899-A1 DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS F11, TFPI, SERPINC1 F11 1/4885KLKB1 5/4885F10 19/4885
US-20100022506-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS TFPI, F11, F12 F11 2/4885KLKB1 53/4885F10 12/4885
US-20110028446-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS TFPI, F11, F12 F11 2/4885KLKB1 53/4885F10 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.